Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN   US45253H1014

IMMUNOGEN, INC. (IMGN)

28
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Sales16,435,559,910171,178,9
Operating income (EBITDA)--68,4-66,9-46,7-88,0-56,6
Operating profit (EBIT)-73,3-73,0-71,5-43,1-105-105
Pre-Tax Profit (EBT)-73,3-72,8----
Net income-73,3-72,8-71,45,86-106-117
EPS ( $)-0,95-0,87-0,83-0,13-1,28-1,33
Dividend per Share ( $)------
Yield------
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Debt------
Finance-195142296218209
Operating income (EBITDA)--68,4-66,9-46,7-88,0-56,6
Leverage
(Debt/EBITDA)
------
Capital Expenditure2,903,778,187,947,755,00
Book Value Per Share (BVPS)-1,44 $0,88 $1,66 $0,59 $1,87 $
Cash Flow per Share--0,72 $-0,63 $0,23 $-1,04 $-
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 869 M$ -
Entreprise Value (EV) 573 M$ 650 M$
Valuation 2015e 2016e
PER (Price / EPS)
Capitalization / Revenue 8,59x 12,2x
EV / Revenue 5,66x 9,15x
EV / EBITDA -12,3x -7,39x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 6,08x 17,0x
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) -42,6% -148%
operating Leverage (Delta EBIT / Delta Sales) 0,58x -4,84x
Net Margin (Net Profit / Revenue) 5,80% -150%
ROA (Net Profit / Asset) -44,6% -
ROE (Net Profit / Equities) -84,2% -42,0%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   7,85% 10,9%
Cash Flow / Sales (Taux d'autofinancement) 20,0% -126%
Capital Intensity (Assets / Sales) -0,13x -
Financial Leverage (Net Debt / EBITDA) 6,34x 2,48x
EPS & Dividend
Dynamic quotes  
ON
| OFF